Leen Kawas, PhD, is a skilled businessperson and biological scientist with a background in managing profitable biopharmaceutical firms. She is well-known for her industry vision, leadership, and innovation as the president and chief executive officer of M3 Biotechnology and a member of the board of directors of Propel Bio.
Dr. Kawas has an MBA from the University of Washington’s Foster School of Business and a Doctorate in molecular pharmacology from Washington State University. She possesses various patents in the field of biotechnology and has written numerous scholarly articles. She is also a popular contributor to media sites and a sought-after speaker at industry events.
M3 Biotechnology has created a pipeline of cutting-edge therapeutic candidates that aim to combat the underlying processes of neurodegenerative illnesses under Leen Kawas‘ leadership. The business is now running a Phase 2a clinical study to evaluate the safety and effectiveness of its main candidate, NDX-1017, in treating moderate cognitive impairment (MCI) linked to Alzheimer’s disease. NDX-1017 has demonstrated encouraging results in preclinical studies.
Kawas is a supporter of inclusion and diversity in the biotech sector. She was selected as one of the 100 Most Influential Women in Business by Forbes in 2020, and DiversityInc identified M3 Biotechnology as one of the 50 Most Diverse Businesses.
Kawas is a prominent participant in the biotech world in addition to her employment at M3 Biotechnology. She is on the board of Life Science Washington, a nonprofit organization that supports the expansion and improvement of the life sciences sector in the state of Washington. She also belongs to the Biotechnology Innovation Organization (BIO), a group of over a thousand biotech businesses, universities, and other organizations.
Leen Kawas is a well-known personality in the biotech sector thanks to her leadership at M3 Biotechnology and dedication to diversity and inclusion. Kawas is well-positioned to have an enduring influence on the pharmaceutical sector thanks to her creative approach to drug development and commitment to the field’s advancement.